



KEYWORD INDEX

#

505(b)(2) C005

A

Acute Lymphoblastic Leukemia (ALL) C009

ADC A006

adolescent A003

AI, clinical, framework B030

AI/ML prioritized precision medicine B023

alternative splicing B005, B006

amyloid precursor protein B005

Anthracyclines B001

Antibody-drug conjugates B027

anti-GD2 Immunotherapy A004

Artificial intelligence C002

ATRX-IFF neuroblastoma B011

B

Bleeding C015

brain cancer A001

Brain Cancer A012

BWS-associated hepatoblastoma C017

C

Computational drug discover B002

cancer predisposition C013

cancer predisposition syndrome C012

Cancer stem cells A016

Cell Fusion A027

Cell state A022, A024

Cell state reporters A019

cell states A015

Cell-free DNA methylation C020

Cell-state plasticity A020

Cell-surface receptors B027



KEYWORD INDEX

Cellular plasticity	A019
cGAS-STING	A016
Chemoresistance	A019
Chemoresistance	A022
Childhood Cancer Data Initiative	C016
Childhood cancer survivors	C003
Chimeric Antigen receptor	A005
Chromatin	B025
Chromatin remodeling	A020
Circulating Tumor DNA	A029
Combination therapies	B013
Consortium	C010
COSMIC Mutational Signatures;	B023
CRISPR–Cas9	C001
CTO Inhibits Calcium channels	B012
CTO Inhibits calcium-sensitive signaling	B012
CTO-Efficacy in three HGG models	B012

D

data visualization	B006
Deep learning	C002
Differentiation	A027
Diffuse hemispheric glioma	C015
Diffuse midline glioma	B018
DNA binding	B024
DNA Damage Response	B017, B021
DNA methylation	C018
DNA Repair	B019
drug repurposing	C005, C006

E

ECM-integrin signaling	C017
epigenetic regulation	B011
Ewing sarcoma	A007, A025, C007
Ewing Sarcoma	A011



KEYWORD INDEX

EWSR1::FLI1 B024, B025

F

FGFR4 A006

Fusion-negative rhabdomyosarcoma A016

G

Gene therapy B002

GD2 A007

GDF15 A002

GEMM A017

Gene editing C001

genetics C008

Genomics C015

Germline C010

Glioblastoma / drug resistance B003

Glutathione A012

Grk2/3 kinases B014

guide RNA (gRNA) C001

H

Hepatoblastoma C023

I

Immune checkpoint A001

Immune checkpoint inhibitors A009

Immune microenvironment A026

Immunotherapy A009, B011

Interpretable machine learning C003

J

There were no keywords in this range.

K

kinase domain mutations B007



KEYWORD INDEX

L

leptomeningeal metastasis	A014, A015
Leukemia	B009
Lineage state	A026
lipocalin-type prostaglandin D2 synthase	C022
liquid biopsy	C019
Liquid biopsy	C020
Liquid Biopsy	A029
low complexity domain	B024

M

medulloblastoma	A014, A015
Medulloblastoma	B014
metaprograms	C014
metastasis	A023
Metastasis	A021, A024
Metastatic	A017
metastatic melanoma	A003
Methylation classification	B026
microglia/macrophage	C022
Mitochondria	A011
molecular characterization initiative	C016
Molecular subtypes	C007
Molecular subtyping	B026
Mouse Model	C021
Multifocal Disease	A010
multi-modal data integration	C016
MYC	A023
MYCN amplification	B008

N

NAD Metabolism	B021
NAMPT	B013, B016
Naxitamab	A004
nephrogenic rest	C013



KEYWORD INDEX

neuroblastoma	B008, C008
Neuroblastoma	A004, A010, A017, A021, A022, A026, A028, B015, B017, B019, C004, C011
Neuroblastoma, CRISPR screen, Menin	B022
Neuro-oncology	B026
neuropeptide Y	A025
NF1	B019
Nigeria	B028
NK-Cell therapy	A002
O	
Oncofusions	A012
oncolytic virus	A008
osteolysis	A025
osteosarcoma	A023
Osteosarcoma	A018, B028
Osteosarcoma, metastasis, heterogeneity	A013
OT-82 resistance	B016
P	
Patient-derived iPSC liver organoid	C017
Pediatric	B028, B029
Pediatric acute lymphoblastic leukemia	C002
Pediatric Blast-Crisis CML	B023
pediatric cancer	C006
Pediatric cancer genomics	C007
Pediatric cancer signaling	B010
pediatric high-grade glioma	C022
Pediatric Oncology	A029
Pediatric Sarcoma	B021
Ph-like ALL	B007
Phosphorylation	B009
PI3K, drug efflux, mitochondria transfer	B020
Pioneer transcription factor	B025
Polyamines	B015



KEYWORD INDEX

Polycomb targets, persistence	B022
PPM1D	B018
predisposition	C008
Predisposition	C010
prodrug	C006
Protein Translation	B015

Q

There were no keywords in this range.

R

rare pediatric cancer	C005
RB1	C019
regulatory circuitry	B004
REST	A002
retinoblastoma	C019
Retinoblastoma, central nervous system tumors	C020
rhabdomyosarcoma	B004
Rhabdomyosarcoma	A006, A020, A024, A027, B013, B016, C018
Rhabdomyosarcoma, drug resistance, Tunnelling Nanotubes	B020
Ribosome biogenesis	B001
Risk stratification	C009

S

Sarcoma	B001
Sarcoma	A005
Second malignant neoplasms	C003
sex bias	C011
single-cell	C014
Single-cell RNA sequencing	B002
Single-cell sequencing, spatial biology, tumor-host interactions	A013
Single-cell transcriptomics	B003
Soft tissue sarcomas	B029



KEYWORD INDEX

Solid tumors	A005
Sonic Hedgehog	B014
Spatial transcriptomics	C023
Stress Granules	A011
Structure-based drug design	B003
surveillance	C012
Survival outcomes	B029
Sympathoadrenal system	A028
Synovial Sarcoma	C021

T

target discovery	B005, B006
Targeted drug delivery	B027
Therapeutic resistance, combinatorial therapy	A013
TP53	B018
Transcription factor	B009
transcriptional inhibitors	B004
TRIM28	A007
tumor associated macrophages	A001
tumor genomics	C012
tumor infiltrating lymphocytes	A003
Tumor initiation	A028
Tumor microenvironment	A009, C023
Tumor Microenvironment	A018, C021
tyrosine kinase inhibitor	B007

U

There were no keywords in this range.

V

viral mimicry	B008
Vasculature	A018

W

wilms tumor	C013
-------------	------

KEYWORD INDEX

X

Xenotransplant C004

Y

Y chromosome C011

Z

Zebrafish A021, C004

Zebrafish A010

Zebrafish ALL models C009